ADC Therapeutic’s Biologics License was approved by the U.S. Food and Drug Administration (FDA) for their relapsed/refractory diffuse large B-cell Lymphoma drug candidate. The antibody conjugate drug, that catalyzes cancer cell death is being investigated in a stage three clinical trial. Another malignancy-killing cancer drug is also in the company’s pipeline, bringing ADC Therapeutics closer to market penetration.  

Read more here.  

More on: